Spoelstra S Kor, Bruins Jojanneke, Bais Leonie, Seerden Paul, Castelein Stynke, Knegtering Henderikus
Addiction Care North Netherlands, Groningen, the Netherlands.
Lentis Psychiatric Institute, Groningen, the Netherlands.
Patient Prefer Adherence. 2022 Mar 4;16:615-624. doi: 10.2147/PPA.S349460. eCollection 2022.
Paliperidone palmitate is the only available long acting injectable (LAI) antipsychotic with a monthly and three-monthly formulation. LAIs may help battle non-adherence. Studies about the experiences of switching from the monthly (PP1M) to the three-monthly formulation (PP3M) of paliperidone are scarce. Therefore, the aim of this study is to evaluate the perspectives of patients, relatives, and mental health professionals on PP3M compared with PP1M.
This was a multicenter, retrospective, non-interventional one-time questionnaire survey among patients with psychotic disorders who switched from PP1M to PP3M (n = 38), their relatives (n = 13) and mental health professionals (n = 38). General satisfaction and (un)desired effects were measured using the Medication Satisfaction Questionnaire (MSQ) and the Subjects' Reaction to Antipsychotics (SRA), respectively. Additional questionnaires assessed socio-demographic variables, preference, effectiveness, side-effects, and confidence in PP3M compared to PP1M.
Mean number of received PP3M injections was 4.2 (SD 2.5). The three study groups reported a high level of confidence in PP3M. High general satisfaction rates about PP3M among patients (69%) and mental health professionals (95%) were reported. The majority of patients, relatives, and mental health professionals reported similar or in some cases even greater effectiveness and similar or in some cases even less side-effects of PP3M compared to PP1M. Sixty-seven percent of the relatives reported less concerns about non-adherence after switching to PP3M.
Most patients, relatives, and mental health professionals prefer PP3M over PP1M. The positive attitudes of all parties may facilitate the more frequent use of PP3M and potentially the clinical outcomes.
棕榈酸帕利哌酮是唯一可用的长效注射用抗精神病药物，有每月一次和每三个月一次的剂型。长效注射剂可能有助于解决依从性问题。关于从棕榈酸帕利哌酮每月剂型（PP1M）转换为每三个月剂型（PP3M）的经验研究很少。因此，本研究的目的是评估患者、家属和心理健康专业人员对PP3M与PP1M的看法。
这是一项多中心、回顾性、非干预性的一次性问卷调查，对象为从PP1M转换为PP3M的精神障碍患者（n = 38）、他们的家属（n = 13）和心理健康专业人员（n = 38）。分别使用药物满意度问卷（MSQ）和受试者对抗精神病药物的反应（SRA）来衡量总体满意度和（不）期望的效果。另外的问卷评估了社会人口统计学变量、偏好、有效性、副作用以及与PP1M相比对PP3M的信心。
接受PP3M注射的平均次数为4.2次（标准差2.5）。三个研究组对PP3M都有很高的信心。报告显示患者（69%）和心理健康专业人员（95%）对PP3M的总体满意度较高。大多数患者、家属和心理健康专业人员报告称，与PP1M相比，PP3M的有效性相似，在某些情况下甚至更高，副作用相似，在某些情况下甚至更少。67%的家属报告称，转换到PP3M后对依从性的担忧减少。
大多数患者、家属和心理健康专业人员更喜欢PP3M而不是PP1M。各方的积极态度可能有助于更频繁地使用PP3M，并可能改善临床结果。
